Search

Haemonetics Corp

Geschlossen

BrancheGesundheitswesen

84.99 -1.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

85.4

Max

88.27

Schlüsselkennzahlen

By Trading Economics

Einkommen

-65M

-20M

Verkäufe

7.4M

346M

KGV

Branchendurchschnitt

38.418

64.641

EPS

1.29

Gewinnspanne

-5.817

Angestellte

3,009

EBITDA

-91M

4.3M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-5.81% downside

Dividenden

By Acuity

Nächstes Ergebnis

6. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.1B

3.6B

Vorheriger Eröffnungskurs

86.6

Vorheriger Schlusskurs

84.99

Nachrichtenstimmung

By Acuity

45%

55%

141 / 340 Ranking in Healthcare

Haemonetics Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Aug. 2026, 19:56 UTC

Haemonetics Corp shares are higher, reflecting broader market gains amid positive momentum in major tech stocks and easing geopolitical tensions.

31. Juli 2026, 20:04 UTC

Haemonetics Corp shares are higher, with no specific news identified. The broader market has also gained since Thursday's close, recovering from earlier losses.

30. Juli 2026, 19:48 UTC

Haemonetics Corp. shares are lower today, continuing a decline since Wednesday. The stock remains above its 20-day moving average despite recent downward movement.

29. Juli 2026, 21:21 UTC

Haemonetics Corp shares are lower in after-market trading, reflecting broader declines in the equity market and Health Care Supplies sector amid rising oil prices.

28. Juli 2026, 21:01 UTC

Haemonetics Corp shares are lower in after-market hours, following a broader market decline amid a significant drop in the Nikkei 225 Index.

27. Juli 2026, 22:51 UTC

Haemonetics Corp shares are higher in after-market trading, supported by falling crude oil prices and strong performance above the 20-day moving average.

24. Juli 2026, 20:31 UTC

Haemonetics Corp shares are lower in after-market hours, continuing a decline from Friday's close. No specific news was identified to explain the movement.

23. Juli 2026, 23:21 UTC

Haemonetics Corp shares are lower in after-market trading, continuing a decline that began after Thursday's close, reaching the midpoint of their one-month trading range.

22. Juli 2026, 20:13 UTC

Shares of Haemonetics Corp are trading higher in after-market hours, positioned above its 20-day moving average amid broader market volatility and rising crude oil prices.

20. Juli 2026, 18:46 UTC

Haemonetics Corp shares are higher today, continuing gains since Friday's close. The stock reached a session high earlier, though it has pulled back.

Peer-Vergleich

Kursveränderung

Haemonetics Corp Prognose

Kursziel

By TipRanks

-5.81% Nachteil

12-Monats-Prognose

Durchschnitt 80.57 USD  -5.81%

Hoch 93 USD

Tief 62 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Haemonetics Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

6

Buy

3

Halten

0

Sell

Stimmung

By Acuity

141 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
help-icon Live chat